{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:32:22Z","timestamp":1786422742810,"version":"build-2736575974"},"reference-count":205,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Immune checkpoint inhibitors (ICIs) and other systemic therapies can extend the survival of many patients with advanced melanoma, renewing interest in complementary strategies for unresectable or metastatic disease. Therapeutic cancer vaccines represent a possible approach. Recent evidence suggests commercially available mRNA vaccines can sensitize tumors to ICIs, challenging prior assumptions about neoantigen presentation. Despite renewed public interest in personalized cancer vaccine development, the proliferation of narrative and scoping reviews has not been matched by systematic mechanistic synthesis\u2014platforms investigated across the 2010s and 2020s have not been rigorously compared within a single article. Accordingly, this review focuses on major vaccine platforms and proposes a comparative framework for understanding therapeutic melanoma vaccine development and immunologic rationale. Methods: Melanoma vaccine clinical trials listed on ClinicalTrials.gov were identified from 2010 to 2025. Eligible studies were screened and included in a qualitative review evaluating trial characteristics, vaccine platforms, study design, and reported outcomes. Results: There is one active Phase III clinical trial for melanoma vaccines in the US. Key principles of melanoma vaccinology include adjuvant, antigen, and delivery platform selection. From 2010 to 2025, four vaccine candidates advanced to Phase III trials, two provided Phase III results for peer review, one trial is ongoing, and no vaccines have been FDA-approved. Inconsistent reporting of outcomes and a lack of published results limited comparability across studies, precluding formal meta-analysis. Conclusions: Therapeutic melanoma vaccine options remain limited by translational challenges in study design and reporting gaps. This review synthesizes contemporary clinical trial activity and immunologic principles to inform future research.<\/jats:p>","DOI":"10.3390\/vaccines14080682","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:00:43Z","timestamp":1786118443000},"page":"682","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Therapeutic Melanoma Vaccines (2010\u20132025)"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3918-8950","authenticated-orcid":false,"given":"Michael Y.","family":"Bian","sequence":"first","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reagan","family":"Stevens","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA"},{"name":"Case Comprehensive Cancer Center, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6789-4315","authenticated-orcid":false,"given":"Ankit","family":"Mangla","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center, Cleveland, OH 44106, USA"},{"name":"Department of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-164X","authenticated-orcid":false,"given":"Devarati","family":"Mitra","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Zaorsky","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center, Cleveland, OH 44106, USA"},{"name":"Department of Radiation Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Bordeaux","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center, Cleveland, OH 44106, USA"},{"name":"Department of Dermatology, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5700-8028","authenticated-orcid":false,"given":"Luke D.","family":"Rothermel","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA"},{"name":"Case Comprehensive Cancer Center, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"(2026, March 01). Melanoma of the Skin\u2014Cancer Stat Facts, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamadermatol.2023.3256","article-title":"Stage-Specific Risk of Recurrence and Death From Melanoma in Denmark, 2008-2021: A National Observational Cohort Study of 25,720 Patients with Stage IA to IV Melanoma","volume":"159","author":"Helvind","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1002\/ijc.30407","article-title":"Epidemiology of cutaneous melanoma in Sweden-Stage-specific survival and rate of recurrence","volume":"139","author":"Rockberg","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2010.09.772","article-title":"Hazard rates for recurrent and secondary cutaneous melanoma: An analysis of 33,384 patients in the German Central Malignant Melanoma Registry","volume":"66","author":"Leiter","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1177\/00031348241241718","article-title":"Stage-Based Detection Methods and Recurrence Patterns for Cutaneous Melanoma","volume":"90","author":"Sullivan","year":"2024","journal-title":"Am. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"115055","DOI":"10.1016\/j.ejca.2024.115055","article-title":"Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy","volume":"212","author":"Woodford","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa2504966","article-title":"Nivolumab for Resected Stage III or IV Melanoma at 9 Years","volume":"394","author":"Ascierto","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Amaral, T., Seeber, O., Mersi, E., Sanchez, S., Thomas, I., Meiwes, A., Forschner, A., Leiter, U., Eigentler, T., and Keim, U. (2020). Primary Resistance to PD-1-Based Immunotherapy\u2014A Study in 319 Patients with Stage IV Melanoma. Cancers, 12.","DOI":"10.3390\/cancers12041027"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1158\/2326-6066.CIR-16-0287","article-title":"Clinical features of acquired resistance to anti\u2013PD-1 therapy in advanced melanoma","volume":"5","author":"Wang","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","article-title":"Cutaneous melanoma","volume":"402","author":"Long","year":"2023","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1200\/JCO.23.01136","article-title":"Systemic Therapy for Melanoma: ASCO Guideline Update","volume":"41","author":"Seth","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"115153","DOI":"10.1016\/j.ejca.2024.115153","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment\u2014Update 2024","volume":"215","author":"Garbe","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.6004\/jnccn.2026.0027","article-title":"Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology","volume":"24","author":"Swetter","year":"2026","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1200\/JCO-25-00765","article-title":"Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients with Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study","volume":"43","author":"Medina","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e005755","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: Pooled analysis of consecutive cohorts of the C-144-01 study","volume":"10","author":"Chesney","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","article-title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","volume":"647","author":"Grippin","year":"2025","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e2500008","DOI":"10.1200\/OA-25-00008","article-title":"Three-Year Update of a Randomized Phase IIb Study of the Individualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus Pembrolizumab Versus Pembrolizumab in Resected Melanoma","volume":"3","author":"Carlino","year":"2026","journal-title":"JCO Oncol. Adv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/CMR.0b013e328346554d","article-title":"Vaccine therapy for metastatic melanoma: Systematic review and meta-analysis of clinical trials","volume":"21","author":"Chi","year":"2011","journal-title":"Melanoma Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","article-title":"Systematic review of medical treatment in melanoma: Current status and future prospects","volume":"16","author":"Garbe","year":"2011","journal-title":"Oncologist"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41587-026-03018-2","article-title":"The promises and challenges of neoantigen cancer vaccines","volume":"44","author":"Ott","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wu, A.C., Nakamura, Y., and Kiyotani, K. (2026). Advances in Neoantigen-Based Cancer Vaccines. Cancers, 18.","DOI":"10.3390\/cancers18010144"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Yu, X., and Fu, K. (2026). Neoantigen-based cancer vaccines: A mechanistic and clinical review of personalised melanoma immunotherapy. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1808146"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1007\/s10147-025-02753-x","article-title":"Efficacy and safety of cancer vaccine therapy in malignant melanoma: A systematic review","volume":"30","author":"Seta","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.semcancer.2003.09.003","article-title":"Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine","volume":"13","author":"Hsueh","year":"2003","journal-title":"Semin. Cancer Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1158\/1078-0432.CCR-08-1231","article-title":"Immunogenicity and antitumor effects of vaccination with peptide vaccine+\/-granulocyte-monocyte colony-stimulating factor and\/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696","volume":"15","author":"Kirkwood","year":"2009","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(18)30254-7","article-title":"MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Dreno","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/annonc\/mdj138","article-title":"Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: A randomized phase III trial of the DC study group of the DeCOG","volume":"17","author":"Schadendorf","year":"2006","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2012.47.9303","article-title":"Adjuvant ganglioside GM2-KLH\/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: Results of the EORTC 18961 randomized phase III trial","volume":"31","author":"Eggermont","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients with Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ebiom.2019.07.066","article-title":"Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma","volume":"47","author":"Andtbacka","year":"2019","journal-title":"eBioMedicine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e006270","DOI":"10.1136\/jitc-2022-006270","article-title":"Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial","volume":"11","author":"Chesney","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined with Pembrolizumab for Advanced Melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1200\/JCO-25-01346","article-title":"RP1 Combined with Nivolumab in Advanced Anti\u2013PD-1\u2013Failed Melanoma (IGNYTE)","volume":"43","author":"Wong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2337s","DOI":"10.1158\/1078-0432.CCR-05-2555","article-title":"Allogeneic and autologous melanoma vaccines: Where have we been and where are we going?","volume":"12","author":"Sondak","year":"2006","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_41","first-page":"505","article-title":"On the Origin of the Vaccine Inoculation","volume":"5","author":"Jenner","year":"1801","journal-title":"Med. Phys. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00000658-189112000-00015","article-title":"Contribution to the Knowledge of Sarcoma","volume":"14","author":"Coley","year":"1891","journal-title":"Ann. Surg."},{"key":"ref_43","first-page":"1","article-title":"The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus)","volume":"3","author":"Coley","year":"1910","journal-title":"Proc. R. Soc. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"(1934). Erysipelas and Prodigiosus Toxins (COLEY). J. Am. Med. Assoc., 103, 1070\u20131071.","DOI":"10.1001\/jama.1934.02750400038015"},{"key":"ref_45","first-page":"154","article-title":"The Toxins of William B. Coley and the Treatment of Bone and Soft-Tissue Sarcomas","volume":"26","author":"McCarthy","year":"2006","journal-title":"Iowa Orthop. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cytogfr.2009.07.004","article-title":"Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley\u2019s legacy revisited","volume":"20","author":"Decker","year":"2009","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jaci.2009.12.980","article-title":"Overview of the Immune Response","volume":"125","author":"Chaplin","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41423-025-01316-4","article-title":"Eliciting antitumor immunity via therapeutic cancer vaccines","volume":"22","author":"Peng","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: From basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.hoc.2024.05.009","article-title":"Advances in Vaccines for Melanoma","volume":"38","author":"Cui","year":"2024","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Zoroddu, S., and Bagella, L. (2025). Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies. Cells, 14.","DOI":"10.3390\/cells14181476"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.coi.2017.07.004","article-title":"Vaccines Targeting Helper T Cells for Cancer Immunotherapy","volume":"47","author":"Melssen","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.it.2012.05.001","article-title":"Focus issue: Structure and function of lymphoid tissues","volume":"33","author":"Thompson","year":"2012","journal-title":"Trends Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2007.06.009","article-title":"Plasticity and heterogeneity of lymphoid organs: What are the criteria to call a lymphoid organ primary, secondary or tertiary?","volume":"112","author":"Pabst","year":"2007","journal-title":"Immunol. Lett."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1398-9995.2004.00531.x","article-title":"Is secondary lymphoid-organ chemokine (SLC\/CCL21) much more than a constitutive chemokine?","volume":"59","author":"Serra","year":"2004","journal-title":"Allergy"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nri2379","article-title":"T-cell activation by dendritic cells in the lymph node: Lessons from the movies","volume":"8","author":"Bousso","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Hunter, M.C., Teijeira, A., and Halin, C. (2016). T Cell Trafficking through Lymphatic Vessels. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00613"},{"key":"ref_59","unstructured":"Cano, R.L.E., and Lopera, H.D.E. (2026, March 04). Introduction to T and B lymphocytes, Autoimmunity: From Bench to Bedside [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459471\/."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.adro.2018.08.018","article-title":"Role of the immunosuppressive microenvironment in immunotherapy","volume":"3","author":"Tormoen","year":"2018","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"446","DOI":"10.21147\/j.issn.1000-9604.2025.03.12","article-title":"Tumor-educated cells in tumor microenvironment: Key drivers of immunotherapy resistance","volume":"37","author":"Zou","year":"2025","journal-title":"Chin. J. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","article-title":"Key chemokines direct migration of immune cells in solid tumors","volume":"29","author":"Kohli","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"925135","DOI":"10.1155\/2012\/925135","article-title":"CD4+ T Cells: Differentiation and Functions","volume":"2012","author":"Luckheeram","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"105086","DOI":"10.1016\/j.critrevonc.2025.105086","article-title":"Potential strategies to improve the therapeutic efficacy of oncolytic viruses for cancer through T and NK cells targeting","volume":"218","author":"Wu","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coche.2017.11.006","article-title":"CD8+ T Cells and NK Cells: Parallel and Complementary Soldiers of Immunotherapy","volume":"19","author":"Rosenberg","year":"2018","journal-title":"Curr. Opin. Chem. Eng."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Uzhachenko, R.V., Gonz\u00e1lez Ochoa, S., Kanagasabai, T., Rajakaruna, H., Thounaojam, M.C., de Aquino, M.T.P., Rana, T., Costa, L., Terekhov, A., and Hofmeister, W.H. (2025). CD8+ T\u2013NK cell crosstalk establishes preemptive immunosurveillance to eliminate antigen\u2013escape tumors. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1593913"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"168297","DOI":"10.1016\/j.jmb.2023.168297","article-title":"DNA Vaccines: History, Molecular Mechanisms and Future Perspectives","volume":"435","author":"Pagliari","year":"2023","journal-title":"J. Mol. Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1080\/21645515.2015.1035502","article-title":"DNA vaccines, electroporation and their applications in cancer treatment","volume":"11","author":"Lee","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e70053","DOI":"10.1111\/1751-7915.70053","article-title":"New insights for the development of efficient DNA vaccines","volume":"17","author":"Berger","year":"2024","journal-title":"Microb. Biotechnol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.biomaterials.2018.09.008","article-title":"Smart vaccine delivery based on microneedle arrays decorated with ultra-pH-responsive copolymers for cancer immunotherapy","volume":"185","author":"Duong","year":"2018","journal-title":"Biomaterials"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/pcmr.12933","article-title":"Strategies in DNA vaccine for melanoma cancer","volume":"34","author":"Rezaei","year":"2021","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials on mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"9925","DOI":"10.1021\/acsnano.5c20535","article-title":"Dual-Targeting mRNA Cancer Vaccines for Simultaneous Antigen Presentation in Dendritic and Tumor Cells","volume":"20","author":"Kim","year":"2026","journal-title":"ACS Nano"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1021\/acsnano.5c16068","article-title":"A Dual-Fusogenic Virus-like Vector Enables Direct Cytosolic Delivery of mRNA Vaccines to Dendritic Cells","volume":"20","author":"Chen","year":"2026","journal-title":"ACS Nano"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s43556-024-00241-8","article-title":"Cancer vaccines: Platforms and current progress","volume":"6","author":"Lei","year":"2025","journal-title":"Mol. Biomed."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"102429","DOI":"10.1016\/j.ctrv.2022.102429","article-title":"Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials","volume":"109","author":"Sobhani","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.21037\/tcr.2020.01.33","article-title":"A review of the research progress in T-lymphocyte immunity and cervical cancer","volume":"9","author":"Zhang","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/14760584.2018.1455505","article-title":"Virus-like antigen display for cancer vaccine development, what is the potential?","volume":"17","author":"Sander","year":"2018","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-15-2667","article-title":"Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ymthe.2005.08.025","article-title":"Immunization with a Lentiviral Vector Stimulates both CD4 and CD8 T Cell Responses to an Ovalbumin Transgene","volume":"13","author":"Rowe","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.4049\/jimmunol.0900008","article-title":"Lentivector Immunization Stimulates Potent CD8 T Cell Responses against Melanoma Self-Antigen Tyrosinase-Related Protein 1 and Generates Antitumor Immunity in Mice","volume":"182","author":"Liu","year":"2009","journal-title":"J. Immunol. Baltim."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/PPO.0b013e3182337a76","article-title":"Autologous Versus Allogeneic Cell-Based Vaccines?","volume":"17","author":"Parmiani","year":"2011","journal-title":"Cancer J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: Advancements, challenges and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.4049\/jimmunol.179.8.5033","article-title":"CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund\u2019s Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity1","volume":"179","author":"Bijker","year":"2007","journal-title":"J. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2300121","DOI":"10.1002\/advs.202300121","article-title":"Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell\/tissue Lysate or Whole Tumor Cell","volume":"10","author":"Diao","year":"2023","journal-title":"Adv. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"100919","DOI":"10.1016\/j.mcpro.2025.100919","article-title":"Integrated Analysis of Proteome and Transcriptome Profiling Reveals Pan-Cancer-Associated Pathways and Molecular Biomarkers","volume":"24","author":"Hu","year":"2025","journal-title":"Mol. Cell. Proteom."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1038\/s41467-019-13368-y","article-title":"Engineering dendritic cell vaccines to improve cancer immunotherapy","volume":"10","author":"Perez","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Barrio-Calvo, M., Kofoed, S.V., Holste, S.C., S\u00f8rensen, A.B., Viborg, N., Kringelum, J.V., Kleine-Kohlbrecher, D., Steenmans, C.S., Thygesen, C.B., and R\u00f8n\u00f8, B. (2023). Targeting neoantigens to APC-surface molecules improves the immunogenicity and anti-tumor efficacy of a DNA cancer vaccine. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1234912"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e947892","DOI":"10.4161\/21624011.2014.947892","article-title":"Two in one: Improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule","volume":"3","author":"Zom","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41551-019-0485-1","article-title":"Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation","volume":"4","author":"Yang","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Kozak, M., and Hu, J. (2024). DNA Vaccines: Their Formulations, Engineering and Delivery. Vaccines, 12.","DOI":"10.3390\/vaccines12010071"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Boudousqui\u00e9, C., Boand, V., Lingre, E., Dutoit, L., Balint, K., Danilo, M., Harari, A., Gannon, P.O., and Kandalaft, L.E. (2020). Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine. Vaccines, 8.","DOI":"10.3390\/vaccines8010025"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.it.2023.11.003","article-title":"The potential of mRNA vaccines in cancer nanomedicine and immunotherapy","volume":"45","author":"Pan","year":"2024","journal-title":"Trends Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e1442169","DOI":"10.1080\/2162402X.2018.1442169","article-title":"Heating it up: Oncolytic viruses make tumors \u2018hot\u2019 and suitable for checkpoint blockade immunotherapies","volume":"7","author":"Gujar","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Nitika Wei, J., and Hui, A.M. (2022). The Delivery of mRNA Vaccines for Therapeutics. Life, 12.","DOI":"10.3390\/life12081254"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Awate, S., Babiuk, L.A., and Mutwiri, G. (2013). Mechanisms of Action of Adjuvants. Front. Immunol., 4.","DOI":"10.3389\/fimmu.2013.00114"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e003533","DOI":"10.1136\/jitc-2021-003533","article-title":"The vaccine-site microenvironment: Impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling","volume":"10","author":"Meneveau","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"P429","DOI":"10.1186\/2051-1426-3-S2-P429","article-title":"Sustained release of actives with MontanideTM ISA 51 VG and MontanideTM ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines","volume":"3","author":"Ascarateil","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1479-5876-5-10","article-title":"Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models","volume":"5","author":"Zhu","year":"2007","journal-title":"J. Transl. Med."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Schmidt, S.T., Christensen, D., and Perrie, Y. (2020). Applying Microfluidics for the Production of the Cationic Liposome-Based Vaccine Adjuvant CAF09b. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12121237"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jconrel.2017.09.041","article-title":"Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA","volume":"266","author":"Verbeke","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e2005191118","DOI":"10.1073\/pnas.2005191118","article-title":"Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2297453","DOI":"10.1080\/21645515.2023.2297453","article-title":"Toll-like receptor agonists as cancer vaccine adjuvants","volume":"20","author":"Jeon","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Lazarus, H.M., Ragsdale, C.E., Gale, R.P., and Lyman, G.H. (2021). Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.706186"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.coi.2011.08.003","article-title":"IL-2 Family Cytokines: New Insights into the Complex Roles of IL-2 as a Broad Regulator of T helper Cell Differentiation","volume":"23","author":"Liao","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/bmt.2015.74","article-title":"Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers","volume":"50","author":"Anandasabapathy","year":"2015","journal-title":"Bone Marrow Transpl."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e010408","DOI":"10.1136\/jitc-2024-010408","article-title":"mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors","volume":"13","author":"Withers","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2447403","DOI":"10.1080\/07853890.2024.2447403","article-title":"The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: A new approach to enhance anti-tumor efficacy","volume":"57","author":"Li","year":"2025","journal-title":"Ann. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jconrel.2016.08.034","article-title":"The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8(+) T-cell responses: The immunological consequences of the biodistribution profile","volume":"239","author":"Schmidt","year":"2016","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Kozak, M., and Hu, J. (2023). The Integrated Consideration of Vaccine Platforms, Adjuvants, and Delivery Routes for Successful Vaccine Development. Vaccines, 11.","DOI":"10.3390\/vaccines11030695"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1086\/313883","article-title":"Improving vaccine performance with adjuvants","volume":"30","author":"Vogel","year":"2000","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/COH.0000000000000052","article-title":"Modulation of HIV-1 immunity by adjuvants","volume":"9","author":"Moody","year":"2014","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.clim.2017.08.004","article-title":"Adjuvant formulations for virus-like particle (VLP) based vaccines","volume":"183","author":"Cimica","year":"2017","journal-title":"Clin. Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/14760584.2021.1991794","article-title":"SARS-CoV-2 subunit vaccine adjuvants and their signaling pathways","volume":"21","author":"Mekonnen","year":"2022","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_120","unstructured":"(2026, March 03). Nanoparticle-Based Delivery Platforms for mRNA Vaccine Development. Available online: https:\/\/www.aimspress.com\/article\/10.3934\/biophy.2020023\/fulltext.html."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Verma, S.K., Mahajan, P., Singh, N.K., Gupta, A., Aggarwal, R., Rappuoli, R., and Johri, A.K. (2023). New-age vaccine adjuvants, their development, and future perspective. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1043109"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1093\/cid\/ciac302","article-title":"Precision Vaccine Adjuvants for Older Adults: A Scoping Review","volume":"75","author":"Nanishi","year":"2022","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e2037640","DOI":"10.1001\/jamanetworkopen.2020.37640","article-title":"Assessment of the Inclusion of Racial\/Ethnic Minority, Female, and Older Individuals in Vaccine Clinical Trials","volume":"4","author":"Flores","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e70053","DOI":"10.1111\/tid.70053","article-title":"Vaccine Adjuvants in the Immunocompromised Host: Science, Safety, and Efficacy","volume":"27","author":"Hayek","year":"2025","journal-title":"Transpl. Infect. Dis."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Megdiche, Y., and Salerno-Gon\u00e7alves, R. (2025). Harnessing adjuvant-induced epigenetic modulation for enhanced immunity in vaccines and cancer therapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1547213"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/j.vaccine.2024.01.100","article-title":"COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals","volume":"42","author":"Faksova","year":"2024","journal-title":"Vaccine"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"103913","DOI":"10.1016\/j.xphs.2025.103913","article-title":"Scale-up and cGMP Manufacturing of Next-Generation Vaccine Adjuvant Saponin\/MPLA NanoParticles (SMNP)","volume":"114","author":"Pallerla","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1053\/j.ajkd.2010.12.016","article-title":"Cost-Effectiveness of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Adult Hemodialysis Patients","volume":"57","author":"Lee","year":"2011","journal-title":"Am. J. Kidney Dis. Off. J. Natl. Kidney Found."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: Mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_131","unstructured":"Zarour, H.M., DeLeo, A., Finn, O.J., and Storkus, W.J. (2026, March 02). Categories of Tumor Antigens, Holland-Frei Cancer Medicine, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK12961\/."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/cmi.2017.30","article-title":"The functions of tumor suppressor PTEN in innate and adaptive immunity","volume":"14","author":"Chen","year":"2017","journal-title":"Cell. Mol. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma","volume":"254","author":"Traversari","year":"1991","journal-title":"Science"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000342164","article-title":"Tumor-Associated Antigens in Breast Cancer","volume":"7","author":"Criscitiello","year":"2012","journal-title":"Breast Care"},{"key":"ref_135","unstructured":"Kr\u00f6ger, N., Gribben, J., Chabannon, C., Yakoub-Agha, I., and Einsele, H. (2026, March 02). What Defines a Good Tumour Antigen?, The EBMT\/EHA CAR-T Cell Handbook, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK584175\/."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s43856-022-00114-7","article-title":"Melanoma-specific antigen-associated antitumor antibody reactivity as an immune-related biomarker for targeted immunotherapies","volume":"2","author":"Jaago","year":"2022","journal-title":"Commun. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3899\/jrheum.190084","article-title":"Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist","volume":"47","author":"Jamal","year":"2020","journal-title":"J. Rheumatol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Nix, M.A., Lareau, C.A., Verboon, J., and Kugler, D.G. (2024). Identifying optimal tumor-associated antigen combinations with single-cell genomics to enable multi-targeting therapies. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1492782"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"a006957","DOI":"10.1101\/cshperspect.a006957","article-title":"T-Cell Tolerance: Central and Peripheral","volume":"4","author":"Xing","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1098\/rstb.2001.0846","article-title":"The thymus and central tolerance","volume":"356","author":"Sprent","year":"2001","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"S885","DOI":"10.1016\/j.annonc.2025.08.2233","article-title":"1605MO Primary results from a randomized phase II trial of BNT111 in combination with cemiplimab with calibrator monotherapy arms in anti-PD-(L)1 relapsed\/refractory melanoma","volume":"36","author":"Ascierto","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_142","unstructured":"Research CDE (2026, March 02). FDA Approves Tebentafusp-Tebn for Unresectable or Metastatic Uveal Melanoma. FDA, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/37876091\/."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: Promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1002\/cncr.31345","article-title":"Melanoma: What do all the mutations mean?","volume":"124","author":"Davis","year":"2018","journal-title":"Cancer"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Georgoulias, G., and Zaravinos, A. (2022). Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1006665"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/2326-6066.CIR-16-0019","article-title":"Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade","volume":"5","author":"Nathanson","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.annonc.2020.05.008","article-title":"Neoantigen prediction and computational perspectives towards clinical benefit: Recommendations from the ESMO Precision Medicine Working Group","volume":"31","author":"Vazquez","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"100052","DOI":"10.1016\/j.iotech.2021.100052","article-title":"Computational cancer neoantigen prediction: Current status and recent advances","volume":"12","author":"Fotakis","year":"2021","journal-title":"Immuno-Oncol. Technol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"ref_152","unstructured":"Clarke, J.J., Colcombe, J.L., and Rigden, D.J. (2025). AlphaFold 3-enabled in silico exploration of PGAM1 interactions in cancer. bioRxiv."},{"key":"ref_153","unstructured":"Ferris, R.L. (2026, March 02). AlphaFold AI Sets Stage for Future Approaches in Cancer|Targeted Oncology-Immunotherapy, Biomarkers, and Cancer Pathways. Available online: https:\/\/www.targetedonc.com\/view\/alphafold-ai-sets-stage-for-future-approaches-in-cancer."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s43018-023-00588-x","article-title":"The landscape of T cell antigens for cancer immunotherapy","volume":"4","author":"Peri","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/1878-0261.13483","article-title":"Neoantigens in cancer immunotherapy: Quantity vs. quality","volume":"17","author":"Wolf","year":"2023","journal-title":"Mol. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s43018-021-00210-y","article-title":"Targeting public neoantigens for cancer immunotherapy","volume":"2","author":"Pearlman","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Apavaloaei, A., Hardy, M.P., Thibault, P., and Perreault, C. (2020). The Origin and Immune Recognition of Tumor-Specific Antigens. Cancers, 12.","DOI":"10.20944\/preprints202008.0649.v1"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: A pan-cancer analysis","volume":"18","author":"Turajlic","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"200978","DOI":"10.1016\/j.omton.2025.200978","article-title":"Shared neoantigens for cancer immunotherapy","volume":"33","author":"Goloudina","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1158\/2326-6066.CIR-19-0541","article-title":"Proteogenomics Uncovers a Vast Repertoire of Shared Tumor-Specific Antigens in Ovarian Cancer","volume":"8","author":"Zhao","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Zhao, P., Effenberger, C., Matsumoto, S., Tanaka, T., Nakamura, Y., and Kiyotani, K. (2025). Identification of shared neoantigens derived from frameshift mutations in the APC gene. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1574955"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41591-019-0434-2","article-title":"Immunogenic neoantigens derived from gene fusions stimulate T cell responses","volume":"25","author":"Yang","year":"2019","journal-title":"Nat. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e008988","DOI":"10.1136\/jitc-2024-008988","article-title":"Comprehensive profiling of cancer neoantigens from aberrant RNA splicing","volume":"12","author":"Wickland","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","article-title":"Alternative tumour-specific antigens","volume":"19","author":"Smith","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"eaau5516","DOI":"10.1126\/scitranslmed.aau5516","article-title":"Noncoding regions are the main source of targetable tumor-specific antigens","volume":"10","author":"Laumont","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/gcc.22733","article-title":"Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions","volume":"58","author":"Stenzinger","year":"2019","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.4155\/bio-2019-0202","article-title":"Harmonization and Standardization of Immunogenicity Assessment of Biotherapeutic Products","volume":"11","author":"Wadhwa","year":"2019","journal-title":"Bioanalysis"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1993522","DOI":"10.1080\/19420862.2021.1993522","article-title":"Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays","volume":"14","author":"Ducret","year":"2021","journal-title":"mAbs"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cels.2018.03.002","article-title":"Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines","volume":"6","author":"Ellrott","year":"2018","journal-title":"Cell Syst."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/bioinformatics\/btab759","article-title":"nextNEOpi: A comprehensive pipeline for computational neoantigen prediction","volume":"38","author":"Rieder","year":"2022","journal-title":"Bioinformatics"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.gim.2022.04.017","article-title":"The Gene Curation Coalition: A global effort to harmonize gene\u2013disease evidence resources","volume":"24","author":"DiStefano","year":"2022","journal-title":"Genet. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.2217\/fon-2022-0694","article-title":"KEYNOTE-D36: Personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma","volume":"18","author":"Long","year":"2022","journal-title":"Future Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"9561","DOI":"10.1200\/JCO.2024.42.16_suppl.9561","article-title":"Immunogenicity of an AI-designed personalized neoantigen vaccine, EVX-01, in combination with anti-PD-1 therapy in patients with metastatic melanoma","volume":"42","author":"Lausen","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"LBA9519","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA9519","article-title":"Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma","volume":"42","author":"Lorigan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"113973","DOI":"10.1016\/j.ejca.2024.113973","article-title":"UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma\u2014A phase II randomised trial","volume":"202","author":"Haakensen","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_176","unstructured":"(2026, March 01). Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination with KEYTRUDA\u00ae (Pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients with High-Risk Stage III\/IV Melanoma Following Complete Resection. Merck.com. Available online: https:\/\/www.merck.com\/news\/moderna-merck-announce-5-year-data-for-intismeran-autogene-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-the-primary-endpoint-of-recurrence-free-survival-i\/."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"LBA9512","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA9512","article-title":"Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial","volume":"42","author":"Weber","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"(2026). Personalized Cancer Vaccine Shows Durable Benefit at 5 Years. Cancer Discov., 16, OF1.","DOI":"10.1158\/2159-8290.CD-NW2026-0009"},{"key":"ref_179","unstructured":"(2026, March 02). News Release. Available online: https:\/\/feeds.issuerdirect.com\/news-release.html?newsid=6695296995122645&symbol=MRNA."},{"key":"ref_180","first-page":"1468","article-title":"Immunization of mice against murine mammary tumor virus infection and mammary tumor development","volume":"38","author":"Sarkar","year":"1978","journal-title":"Cancer Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1182\/blood-2002-10-3108","article-title":"Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity","volume":"101","author":"Zeng","year":"2003","journal-title":"Blood"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"8085","DOI":"10.1158\/0008-5472.CAN-04-1871","article-title":"Cargo from Tumor-Expressed Albumin Inhibits T-Cell Activation and Responses","volume":"64","author":"Graner","year":"2004","journal-title":"Cancer Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4161\/hv.26568","article-title":"Allogeneic tumor cell vaccines","volume":"10","author":"Srivatsan","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"106288","DOI":"10.1016\/j.isci.2023.106288","article-title":"Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity","volume":"26","author":"Fritah","year":"2023","journal-title":"iScience"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12967-020-02570-y","article-title":"In vivo vaccination with cell line-derived whole tumor lysates: Neoantigen quality, not quantity matters","volume":"18","author":"Salewski","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Broderick, J.C., Adams, A.M., Barbera, E.L., Van Decar, S., Clifton, G.T., and Peoples, G.E. (2025). Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients. Vaccines, 13.","DOI":"10.3390\/vaccines13060656"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00262-022-03272-8","article-title":"Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: A randomized clinical trial","volume":"72","author":"Adams","year":"2023","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1245\/s10434-021-09709-1","article-title":"A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III\/IV Melanoma: A Primary Analysis","volume":"28","author":"Vreeland","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"e006665","DOI":"10.1136\/jitc-2023-006665","article-title":"Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III\/IV melanoma: A prespecified 36-month analysis","volume":"11","author":"Carpenter","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_190","first-page":"100843","article-title":"Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III\/IV melanoma patients: Results of a phase I\/IIa trial","volume":"41","author":"Carpenter","year":"2024","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/jamaoncol.2023.7333","article-title":"Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis","volume":"10","author":"Mangla","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"e108254","DOI":"10.1136\/bmjopen-2025-108254","article-title":"Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: A systematic review of randomised controlled trials","volume":"15","author":"Peinemann","year":"2025","journal-title":"BMJ Open"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/SLA.0000000000001573","article-title":"Underreporting of Secondary Endpoints in Randomized Trials: Cross-sectional, Observational Study","volume":"264","author":"Matthews","year":"2016","journal-title":"Ann. Surg."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"e023001","DOI":"10.1136\/bmjopen-2018-023001","article-title":"Guidance for reporting outcomes in clinical trials: Scoping review protocol","volume":"9","author":"Butcher","year":"2019","journal-title":"BMJ Open"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13063-019-3248-0","article-title":"Improving outcome reporting in clinical trial reports and protocols: Study protocol for the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT)","volume":"20","author":"Butcher","year":"2019","journal-title":"Trials"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41467-024-45358-0","article-title":"Adjuvant dendritic cell therapy in stage IIIB\/C melanoma: The MIND-DC randomized phase III trial","volume":"15","author":"Bol","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_197","unstructured":"Research CDE (2026, March 04). FDA Approves Pembrolizumab for Adjuvant Treatment of Melanoma. FDA, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-adjuvant-treatment-melanoma."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/CJI.0b013e31826f79c8","article-title":"Tumor stem cell antigens as consolidative active specific immunotherapy: A randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma","volume":"35","author":"Dillman","year":"2012","journal-title":"J. Immunother."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40425-018-0330-1","article-title":"Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses","volume":"6","author":"Dillman","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1007\/s00262-020-02618-4","article-title":"A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III\/IV melanoma patients who are disease-free following the resection of macrometastases","volume":"69","author":"Jansen","year":"2020","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_202","unstructured":"Waldron, J. (2026, March 04). IO Lays off 50% After FDA Derails Cancer Vaccine Approval Plan. Available online: https:\/\/www.fiercebiotech.com\/biotech\/io-lays-50-employees-after-fda-derails-cancer-vaccine-approval-plan."},{"key":"ref_203","unstructured":"(2026, March 04). IO Biotech Admits Defeat. ApexOnco. Available online: https:\/\/www.apexonco.com\/io-biotech-admits-defeat."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Bulgarelli, J., Tazzari, M., Granato, A.M., Ridolfi, L., Maiocchi, S., de Rosa, F., Petrini, M., Pancisi, E., Gentili, G., and Vergani, B. (2019). Dendritic Cell Vaccination in Metastatic Melanoma Turns \u201cNon-T Cell Inflamed\u201d Into \u201cT-Cell Inflamed\u201d Tumors. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02353"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/8\/682\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:26:47Z","timestamp":1786422407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/8\/682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":205,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["vaccines14080682"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14080682","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]}}}